TAK - Takeda Pharmaceutical Company Limited
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Tokyo,
Japan
Type: Equity
TAK price evolution
TAK
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 Feb 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $277613.76 | |||
| Short term investments | $200670.89 | |||
| Net receivables | $715389.33 | $743079 | ||
| Inventory | $1126055.21 | $1169640 | ||
| Total current assets | $2338322.52 | $2428830 | ||
| Long term investments | $11354628.82 | |||
| Property, plant & equipment | $1772878.45 | $1841499 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $13692951.34 | $14222947 | ||
| Current liabilities | ||||
| Accounts payable | $465642.95 | $483666 | ||
| Deferred revenue | ||||
| Short long term debt | $595348.6 | |||
| Total current liabilities | $2197126.61 | $2282168 | ||
| Long term debt | $4655792.17 | $4293872 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $7202244.86 | $7481013 | ||
| Shareholders' equity | ||||
| Retained earnings | $1344787.04 | $1396838 | ||
| Other shareholder equity | $1977951 | |||
| Total shareholder equity | $6490707.44 | |||
| (in millions $) | 28 Jun 2023 | 29 Jun 2022 | 1 May 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $545648.18 | $941341.81 | $849695 | $9082.49 |
| Short term investments | $185154.05 | $184352.08 | $330.52 | |
| Net receivables | $697176.44 | $802507.2 | $724377 | $7639.51 |
| Inventory | $1008863.63 | $945187.19 | $853167 | $6808.34 |
| Total current assets | $2452423.33 | $2873388.28 | $2593642 | $24500.29 |
| Long term investments | $11822354.06 | $11725990.68 | $96579 | $3145.97 |
| Property, plant & equipment | $1729642.24 | $1753518.4 | $1582800 | $13666.82 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $95874.37 | |||
| Total investments | ||||
| Total assets | $14274777.4 | $14599378.96 | $13178018 | $116611.66 |
| Current liabilities | ||||
| Accounts payable | $663979.17 | $571984.01 | $516297 | $3105.22 |
| Deferred revenue | ||||
| Short long term debt | $537064.55 | $443214.29 | $203708 | $22153 |
| Total current liabilities | $2538312.83 | $2377165.17 | $2145730 | $16013.65 |
| Long term debt | $4680968.6 | $5107627.52 | $4141418 | $41662.24 |
| Total noncurrent liabilities | $56042.24 | |||
| Total debt | $46537.47 | |||
| Total liabilities | $7776331.85 | $8303399.29 | $7494999 | $69856.28 |
| Shareholders' equity | ||||
| Retained earnings | $1576150.38 | $1639315.92 | $1479716 | $13636.05 |
| Other shareholder equity | $1495649 | $934174 | $3306.4 | |
| Total shareholder equity | $6498445.55 | $6295979.67 | $5683019 | $5173037 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 Feb 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1069779.41 | $1111186 | ||
| Cost of revenue | $365340.24 | |||
| Gross Profit | $704439.17 | $731705 | ||
| Operating activities | ||||
| Research & development | $180398.54 | |||
| Selling, general & administrative | $257551.29 | |||
| Total operating expenses | $934428.27 | $601604 | ||
| Operating income | $135351.14 | |||
| Income from continuing operations | ||||
| EBIT | $135351.14 | |||
| Income tax expense | -$42837.93 | -$44496 | ||
| Interest expense | -$43654 | |||
| Net income | ||||
| Net income | $101780.51 | $105718 | ||
| Income (for common shares) | $101780.51 | |||
| (in millions $) | 28 Jun 2023 | 29 Jun 2022 | 1 May 2022 | 1 May 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4118954.97 | $3953953.55 | $3569006 | $30059.43 |
| Cost of revenue | $1272328.87 | $1226228.72 | $994308 | |
| Gross Profit | $2846626.09 | $2727724.83 | $2462160 | $20712.94 |
| Operating activities | ||||
| Research & development | $647709.85 | $582829.94 | $456133 | |
| Selling, general & administrative | $1019961.09 | $981962.55 | $873763 | |
| Total operating expenses | $3507253.83 | $3341113.94 | $2001316 | $15926.3 |
| Operating income | $611701.14 | $612839.61 | $4787.13 | |
| Income from continuing operations | ||||
| EBIT | $611701.14 | $612839.61 | $389369 | |
| Income tax expense | $59370.55 | $80214.49 | $72405 | -$93.4 |
| Interest expense | -$158274 | $2337.13 | ||
| Net income | ||||
| Net income | $324217.47 | $255108.79 | $230059 | $3534.45 |
| Income (for common shares) | $324217.47 | $255108.79 | $376005 | |
| (in millions $) | 1 Feb 2024 | 31 Jan 2024 | 30 Oct 2023 | 28 Jun 2023 |
|---|---|---|---|---|
| Net income | $101780.51 | $38446.17 | ||
| Operating activities | ||||
| Depreciation | $199152.11 | $158643.26 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $156671.76 | $291621.67 | ||
| Investing activities | ||||
| Capital expenditures | -$92508.96 | -$451741.52 | ||
| Investments | ||||
| Total cash flows from investing | -$90065.24 | -$402378 | -$327109 | -$446295.16 |
| Financing activities | ||||
| Dividends paid | -$278062 | -$139811 | ||
| Sale and purchase of stock | ||||
| Net borrowings | $4772856.13 | $4487230.93 | ||
| Total cash flows from financing | -$104796.04 | -$296193 | -$198433 | $2234.15 |
| Effect of exchange rate | $15644 | $18759 | ||
| Change in cash and equivalents | $277613.76 | -$245171 | -$215478 | $545648.18 |
| (in millions $) | 28 Jun 2023 | 29 Jun 2022 | 1 May 2022 | 1 May 2021 |
|---|---|---|---|---|
| Net income | $324217.47 | $255108.79 | $3536.01 | |
| Operating activities | ||||
| Depreciation | $679490.66 | $646048.78 | $559671 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $999351.38 | $1244243.61 | $9502.75 | |
| Investing activities | ||||
| Capital expenditures | -$648082.11 | -$206102.67 | -$111206 | |
| Investments | $62008 | |||
| Total cash flows from investing | -$620891.24 | -$219495.57 | -$198125 | $3699.18 |
| Financing activities | ||||
| Dividends paid | -$283665 | -$2663.56 | ||
| Sale and purchase of stock | ||||
| Net borrowings | $4487230.93 | $4425147.92 | -$660504 | |
| Total cash flows from financing | -$725256.05 | -$1185702.15 | -$1070265 | -$10230.53 |
| Effect of exchange rate | $28758 | $117.51 | ||
| Change in cash and equivalents | -$398196.07 | -$238792.86 | -$116527 | $3088.91 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |